Evidence-Based Strategies for Managing Fabry Disease: Considerations for Novel Therapies to Improve Outcomes
Released On
December 20, 2023
Expires On
September 29, 2024
Media Type
Internet
Completion Time
60 minutes
This activity is provided by Med Learning Group.
This activity is co-provided by AMEDCO.
Nursing learners, view this Learner Notification prior to starting this activity
This activity is supported by an independent educational grant from Amicus Therapeutics, Inc.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Nurses — 1.0 ANCC contact hour
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity is specifically designed for U.S.-based healthcare professionals involved in the diagnosis, treatment, or management of patients with Fabry disease, including geneticists, genetic counselors, nephrologists, cardiologists, pediatricians, endocrinologists, primary care physicians, nurses, nurse practitioners, and physician assistants.
Program Overview
This program uses an interactive, game-based format to provide the most recent information on the pathophysiology, diagnosis, and management of Fabry disease. It includes video case studies and interactive questions throughout the presentation.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify the characteristic symptoms and signs of Fabry disease (FD) in patients to facilitate timely diagnosis and management
- Evaluate the clinical evidence supporting approved and investigational therapies for FD, including real-world data, to inform treatment decisions
- Develop effective communication skills to educate patients and caregivers about FD and its management, tailored to the patient’s needs and preferences
- Analyze the risk factors and clinical features of cardiac and renal complications in patients with FD and select appropriate tools to assess disease progression and treatment response
- Assess the impact of early intervention on the efficacy of FD treatment, disease progression, and patients’ quality of life
Faculty
Dawn Laney, MS, CGC , CCRC
Genetic Counselor/Assistant Professor
Emory University School of Medicine
Division of Medical Genetics
Atlanta, GA
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
Physician Credit Designation Statement
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™ Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nurses(ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hours.
Disclosure Policy Statement
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Disclosure of Relevant Financial Relationships
Dawn Laney, MS Ms. Laney discloses that she has received honoraria and research funding as an investigator, researcher, speaker, board member registries/coordinator for Sanofi Genzyme; has received research funding and honoraria as an investigator, speaker, coordinator for Amicus and Shire, now part of Takeda; and is a cofounder and has stock options for ThinkGenetic, Inc.
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Debra Gordon, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Associate Program Manager for Med Learning Group, has nothing to disclose.
Daniel Dasilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
Jacquelyn Sandfort, Program Coordinator for Med Learning Group, has nothing to disclose.
Method of Participation
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Disclaimer
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: https://www.medlearninggroup.com/privacy-policy/
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Content - Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.